References
- Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G : MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26 : 2192-2197, 2008 https://doi.org/10.1200/JCO.2007.14.8163
- Caroline I, Rosenthal MA : Imaging modalities in high-grade gliomas : pseudoprogression, recurrence, or necrosis? J Clin Neurosci 19 : 633-637, 2012 https://doi.org/10.1016/j.jocn.2011.10.003
- Chamberlain MC : Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 5 : 117-129, 2011
- Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H : Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma : clinical observations and working recommendations. Surg Neurol 72 : 423-428, 2009 https://doi.org/10.1016/j.surneu.2008.09.023
- Easaw JC, Mason WP, Perry J, Laperrière N, Eisenstat DD, Del Maestro R, et al. : Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 18 : e126-e136, 2011
- Fauquette W, Amourette C, Dehouck MP, Diserbo M : Radiation-induced blood-brain barrier damages : an in vitro study. Brain Res 1433 : 114-126, 2012 https://doi.org/10.1016/j.brainres.2011.11.022
- Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. : Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27 : 4733-4740, 2009 https://doi.org/10.1200/JCO.2008.19.8721
- Gallego Perez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, Gonzalez-Aguilar A, Houillier C, et al. : Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab : comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 14 : 667-673, 2012 https://doi.org/10.1093/neuonc/nos070
- Joo JD, Chang JH, Kim JH, Hong YK, Kim YH, Kim CY : Temozolomide during and after radiotherapy for newly diagnosed glioblastomas : a prospective multicenter study of Korean patients. J Korean Neurosurg Soc 52 : 92-97, 2012 https://doi.org/10.3340/jkns.2012.52.2.92
- Kang HC, Kim CY, Han JH, Choe GY, Kim JH, Kim JH, et al. : Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy : potential role of p53. J Neurooncol 102 : 157-162, 2011 https://doi.org/10.1007/s11060-010-0305-7
- Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. : Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27 : 740-745, 2009 https://doi.org/10.1200/JCO.2008.16.3055
- Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, et al. : Progression-free survival : an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10 : 162-170, 2008 https://doi.org/10.1215/15228517-2007-062
- Laymon CM, Oborski MJ, Lee VK, Davis DK, Wiener EC, Lieberman FS, et al. : Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme : correlating sodium MRI and F-18 FLT PET on a voxel-wise basis. Magn Reson Imaging 30 : 1268-1278, 2012 https://doi.org/10.1016/j.mri.2012.05.011
- Lutz K, Radbruch A, Wiestler B, Bäumer P, Wick W, Bendszus M : Neuroradiological response criteria for high-grade gliomas. Clin Neuroradiol 21 : 199-205, 2011 https://doi.org/10.1007/s00062-011-0080-7
- Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG : Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 : 1277-1280, 1990
- Mangla R, Singh G, Ziegelitz D, Milano MT, Korones DN, Zhong J, et al. : Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 256 : 575-584, 2010 https://doi.org/10.1148/radiol.10091440
- Miyatake S, Furuse M, Kawabata S, Maruyama T, Kumabe T, Kuroiwa T, et al. : Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases. Neuro Oncol 15 : 650-655, 2013 https://doi.org/10.1093/neuonc/not020
- Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, et al. : An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92 : 149-155, 2009 https://doi.org/10.1007/s11060-008-9745-8
- Pan E, Tsai JS, Mitchell SB : Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients. Anticancer Res 29 : 4309-4313, 2009
- Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, et al. : A new model for prediction of drug distribution in tumor and normal tissues : pharmacokinetics of temozolomide in glioma patients. Cancer Res 69 : 120-127, 2009 https://doi.org/10.1158/0008-5472.CAN-08-2356
- Sanghera P, Perry J, Sahgal A, Symons S, Aviv R, Morrison M, et al. : Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37 : 36-42, 2010 https://doi.org/10.1017/S0317167100009628
- Sanghera P, Rampling R, Haylock B, Jefferies S, McBain C, Rees JH, et al. : The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas. Clin Oncol (R Coll Radiol) 24 : 216-227, 2012 https://doi.org/10.1016/j.clon.2011.06.004
- Scherrmann JM : Expression and function of multidrug resistance transporters at the blood-brain barriers. Expert Opin Drug Metab Toxicol 1 : 233-246, 2005 https://doi.org/10.1517/17425255.1.2.233
- Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, et al. : Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113 : 405-410, 2008 https://doi.org/10.1002/cncr.23562
- Thompson EM, Frenkel EP, Neuwelt EA : The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 76 : 87-93, 2011 https://doi.org/10.1212/WNL.0b013e318204a3af
- Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, et al. : Application of novel response/progression measures for surgically delivered therapies for gliomas : Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 70 : 234-243; discussion 243-244, 2012 https://doi.org/10.1227/NEU.0b013e318223f5a7
- Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, et al. : Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 : 1253-1259, 2007 https://doi.org/10.1158/1078-0432.CCR-06-2309
- Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. : Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group. J Clin Oncol 28 : 1963-1972, 2010 https://doi.org/10.1200/JCO.2009.26.3541
- Young RJ, Gupta A, Shah AD, Graber JJ, Chan TA, Zhang Z, et al. : MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging 37 : 41-49, 2013 https://doi.org/10.1016/j.clinimag.2012.02.016
Cited by
- Advanced Magnetic Resonance Imaging Methods for Planning and Monitoring Radiation Therapy in Patients With High-Grade Glioma vol.24, pp.4, 2014, https://doi.org/10.1016/j.semradonc.2014.06.008
- Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma vol.129, pp.1, 2016, https://doi.org/10.1007/s11060-016-2151-8
- Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis vol.20, pp.8, 2014, https://doi.org/10.1007/s12094-017-1816-x
- Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response vol.2018, pp.None, 2014, https://doi.org/10.1155/2018/2908609
- Current concepts in radiologic assessment of pediatric brain tumors during treatment, part 1 vol.48, pp.13, 2018, https://doi.org/10.1007/s00247-018-4194-9
- The Path Toward PET-Guided Radiation Therapy for Glioblastoma in Laboratory Animals: A Mini Review vol.6, pp.None, 2014, https://doi.org/10.3389/fmed.2019.00005
- Blood Biomarkers of Glioma in Response Assessment Including Pseudoprogression and Other Treatment Effects: A Systematic Review vol.10, pp.None, 2014, https://doi.org/10.3389/fonc.2020.01191
- Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 – Radiological features and metric markers vol.159, pp.None, 2014, https://doi.org/10.1016/j.critrevonc.2021.103230
- A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma vol.27, pp.23, 2014, https://doi.org/10.1158/1078-0432.ccr-21-0544